Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07513818
Recruiting Not applicable

Implementing Low-dose ct Lung Cancer Screening in France.

NCT07513818 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-05-11
Last updated
2026-06-05

Condition(s) studied

Lung Cancer

Investigational drug(s) / intervention(s)

Low-dose computed tomography of the chest

Low-dose computed tomography of the chest: Baseline low-dose CT acquisition, then at 1 year and 3 years to depict suspicious lung nodules

Study summary

The main objective is to estimate the detection rate of lung cancer in the population screened by low-dose chest CT scans.

Eligibility

Sex
ALL
Min age
50 Years
Max age
74 Years
Healthy volunteers
No
Inclusion Criteria: * Adults aged 50-74 years * Active or former smoker having quit less than 15 years ago * Smoking history of at least 20 pack-years, or 15 cigarettes/day for 25 years or 10 cigarettes/day for 30 years * Affiliation with a social security scheme * Written informed consent prior to study participation Temporary exclusion Criteria * Chest CT scan performed within the previous 12 months * Signs of respiratory infection (fever, productive cough) Exclusion Criteria: * Severe co-morbidities contraindicating exploration and/or management (including stereotactic surgery or radiotherapy) of lung cancers * Poor general status (PS2 and above) * Rest dyspnea (mMRC4) * Cancer under active surveillance by thoracic computed tomography (CT pr PET-CT) * Personal history of lung cancer * Symptoms raising suspicion of lung cancer (hemoptysis, unexplained weight loss, recent onset or modification of respiratory symptoms,…)

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
HCL - Hôpital Lyon Sud Lyon France Not Yet Recruiting
Hôpital Cochin Paris Île-de-France Region Recruiting

More Assistance Publique - Hôpitaux de Paris trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07513818 on ClinicalTrials.gov ↗ ← All trials in France